[go: up one dir, main page]

MX2017011879A - Inhibidores de pcsk9 para el tratamiento de trastornos del metabolismo de lipoproteínas". - Google Patents

Inhibidores de pcsk9 para el tratamiento de trastornos del metabolismo de lipoproteínas".

Info

Publication number
MX2017011879A
MX2017011879A MX2017011879A MX2017011879A MX2017011879A MX 2017011879 A MX2017011879 A MX 2017011879A MX 2017011879 A MX2017011879 A MX 2017011879A MX 2017011879 A MX2017011879 A MX 2017011879A MX 2017011879 A MX2017011879 A MX 2017011879A
Authority
MX
Mexico
Prior art keywords
treatment
metabolism disorders
lipoprotein metabolism
pcsk9 inhibitors
pcsk9
Prior art date
Application number
MX2017011879A
Other languages
English (en)
Other versions
MX384944B (es
Inventor
Gustafsen Camilla
Glerup Pedersen Simon
S?Ndergaard Madsen Peder
Original Assignee
Univ Aarhus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Aarhus filed Critical Univ Aarhus
Publication of MX2017011879A publication Critical patent/MX2017011879A/es
Publication of MX384944B publication Critical patent/MX384944B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Biophysics (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente divulgación hace referencia a inhibidores de proteína convertasa subtilisina/kexina tipo 9 (PCSK9) para el tratamiento de trastornos del metabolismo de lipoproteínas.
MX2017011879A 2015-03-20 2016-03-18 Inhibidores de pcsk9 para el tratamiento de trastornos del metabolismo de lipoproteínas". MX384944B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA201570158 2015-03-20
DKPA201570623 2015-10-02
DKPA201570839 2015-12-21
PCT/DK2016/050082 WO2016150444A1 (en) 2015-03-20 2016-03-18 Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders

Publications (2)

Publication Number Publication Date
MX2017011879A true MX2017011879A (es) 2018-04-10
MX384944B MX384944B (es) 2025-03-14

Family

ID=55696811

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011879A MX384944B (es) 2015-03-20 2016-03-18 Inhibidores de pcsk9 para el tratamiento de trastornos del metabolismo de lipoproteínas".

Country Status (10)

Country Link
US (3) US10688119B2 (es)
EP (2) EP3271405A1 (es)
JP (2) JP6869894B2 (es)
KR (1) KR20170123345A (es)
CN (1) CN107531798B (es)
AU (2) AU2016235662B2 (es)
BR (1) BR112017020091A2 (es)
CA (1) CA2979756A1 (es)
MX (1) MX384944B (es)
WO (1) WO2016150444A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170123345A (ko) 2015-03-20 2017-11-07 오르후스 우니베르시테트 지질단백질 대사 장애의 치료를 위한 pcsk9의 억제제
JP7046381B2 (ja) * 2016-09-20 2022-04-04 オーフス ウニベルシテット リポタンパク質代謝障害の治療のための化合物
CN108753821A (zh) * 2018-06-13 2018-11-06 黄河科技学院 一种基于细胞的pcsk9抑制剂筛选方法
WO2020010186A1 (en) * 2018-07-06 2020-01-09 Derek Klarin Pcsk9 variants

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3422407A1 (de) * 1984-06-16 1986-03-06 B. Braun Melsungen Ag, 3508 Melsungen Verwendung von heparinderivaten zur selektiven extrakorporalen praezipitation von low-density-lipoproteinen aus vollserum oder plasma
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2114948T3 (es) 1991-10-04 1998-06-16 Procter & Gamble Compuestos disminuidores del colesterol y procedimiento para prepararlos.
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
GB9221657D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
WO1994013806A1 (en) 1992-12-11 1994-06-23 The Dow Chemical Company Multivalent single chain antibodies
US6255296B1 (en) * 1994-01-11 2001-07-03 Endomatrix, Inc. Composition and method for treating a patient susceptible to or suffering from a cardiovascular disorder or disease
US6258798B1 (en) * 1999-09-07 2001-07-10 Pharmacia Ab Method for treatment of unstable coronary artery disease by an early revascularisation together with administration of a low molecular weight heparin
ES2295228T3 (es) 2000-11-30 2008-04-16 Medarex, Inc. Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos.
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
UA80399C2 (en) * 2001-11-13 2007-09-25 Glaxo Group Ltd Use of specific dose of fondaparinux sodium for the treatment of acs
JP4554910B2 (ja) * 2002-11-01 2010-09-29 生化学工業株式会社 血糖低下剤
CA2517416A1 (en) * 2003-02-28 2004-09-10 Howard Florey Institute Of Experimental Physiology And Medicine Therapeutic compositions
ES2603379T3 (es) * 2006-10-09 2017-02-27 Roche Innovation Center Copenhagen A/S Compuestos antagonistas de ARN para la modulación de PCSK9
WO2008118883A1 (en) * 2007-03-24 2008-10-02 Isis Pharmaceuticals, Inc. Administering antisense oligonucleotides complementary to human apolipoprotein b
JOP20080381B1 (ar) * 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
WO2009049370A1 (en) 2007-10-16 2009-04-23 Progen Pharmaceuticals Limited Novel sulfated oligosaccharide derivatives
US8598320B2 (en) * 2007-10-26 2013-12-03 Merck Sharp & Dohme Corp. Anti-PCSK9 and methods for treating lipid and cholesterol disorders
ES2340902B1 (es) * 2008-07-01 2011-05-03 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con glicosaminoglicanos y su uso en tratamiento de ulceras cronicas.
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
CN101757019B (zh) * 2008-11-10 2011-06-08 鲁南制药集团股份有限公司 用于减肥或治疗代谢综合征的药物组合物
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
ES2537652T3 (es) * 2009-10-01 2015-06-10 Cadila Healthcare Limited Compuestos para el tratamiento de la Dislipidemia y enfermedades relacionadas
EP2495242B1 (en) 2009-10-29 2016-05-04 Industry-Academic Cooperation Foundation Yonsei University Novel vascular leak inhibitor
AR079336A1 (es) * 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
US20120195910A1 (en) * 2010-12-22 2012-08-02 Genentech, Inc. Anti-pcsk9 antibodies and methods of use
CN102526739B (zh) * 2010-12-27 2014-12-03 鲁南制药集团股份有限公司 治疗糖尿病的药物组合物及其应用
KR20200133826A (ko) * 2011-01-28 2020-11-30 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 특정 대상자 그룹의 치료 방법에 이용하기 위한 ｐｃｓｋ9에 대한 인간 항체
EA201391157A1 (ru) 2011-02-11 2014-02-28 АйАрЭм ЭлЭлСи Антагонисты pcsk9
AR087715A1 (es) * 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
US9879093B2 (en) 2011-12-20 2018-01-30 Adaerata, Limited Partnershp Single domain antibodies as inhibitors of PCSK9
WO2013148284A1 (en) 2012-03-29 2013-10-03 Genentech, Inc. Antibodies that bind to a pcsk9 cleavage site and methods of use
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
KR20150059638A (ko) 2012-05-25 2015-06-01 카타베이시스 파마슈티칼즈, 인코포레이티드 전구단백질 전환효소 섭틸리신/켁신 9형 저하 방법
CA2877766A1 (en) * 2012-07-03 2014-01-09 Majambu Mbikay Quercetin-3-glucoside and uses thereof
WO2014107739A1 (en) * 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
CA2906508A1 (en) * 2013-03-15 2014-09-25 Amgen, Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
US20160031935A1 (en) * 2013-03-15 2016-02-04 Adaerata, Limited Partnership Small molecule modulators of pcsk9 and methods of use thereof
US9480703B2 (en) * 2013-10-29 2016-11-01 Shaker A. Mousa Method and composition of glycosaminoglycans in sickle cell and vascular disorders
KR20170123345A (ko) 2015-03-20 2017-11-07 오르후스 우니베르시테트 지질단백질 대사 장애의 치료를 위한 pcsk9의 억제제
JP7046381B2 (ja) * 2016-09-20 2022-04-04 オーフス ウニベルシテット リポタンパク質代謝障害の治療のための化合物

Also Published As

Publication number Publication date
KR20170123345A (ko) 2017-11-07
WO2016150444A1 (en) 2016-09-29
EP3973958A2 (en) 2022-03-30
CN107531798A (zh) 2018-01-02
JP2018511596A (ja) 2018-04-26
JP2021119148A (ja) 2021-08-12
AU2020256388A1 (en) 2020-11-12
EP3271405A1 (en) 2018-01-24
CN107531798B (zh) 2022-02-18
EP3973958A3 (en) 2022-06-22
AU2016235662B2 (en) 2020-07-30
BR112017020091A2 (pt) 2018-11-06
JP6869894B2 (ja) 2021-05-12
MX384944B (es) 2025-03-14
US20220072032A1 (en) 2022-03-10
US20200330504A1 (en) 2020-10-22
US10688119B2 (en) 2020-06-23
AU2016235662A1 (en) 2017-10-12
US20180193376A1 (en) 2018-07-12
CA2979756A1 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
UY36550A (es) Oligómeros antisentido de tau y sus usos
ECSP18073726A (es) Inhibidores del enlace proteína-proteína de wdr5
MX2023000251A (es) Composiciones para usarse en el tratamiento de un trastorno asociado a gen de proproteina convertasa subtilisina kexina (pcsk9).
CL2017002066A1 (es) Proteasas de cisteína
SV2018005661A (es) Composiciones oligonucleotidicas y sus metodos
ECSP19043710A (es) Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas
CO2018003828A2 (es) Ácido (s) -3-amino-4- (difluorometilenil) ciclopent-1-eno-1-carboxílico, y compuestos relacionados como inactivadores de gaba aminotransferasa
MX2021001439A (es) Composiciones y metodos para el tratamiento de la disfuncion de la glandula de meibomio.
ECSP17083788A (es) Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38
UY37391A (es) Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad y altamente concentradas, kits, y métodos
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
MX2018001706A (es) Sales de un inhibidor de dimetilasa 1 especifica para lisina (lsd1).
PE20171042A1 (es) Inhibidores del bromodominio
MX372669B (es) Un compuesto que modifica el empalme del gen de foxm1 para usarse en la profilaxis o tratamiento de cáncer.
CO6791571A2 (es) Moduladores de la proteína tirosina quinasa 7 (ptk7) para el tratamiento diagnóstico o profilaxis de trastornos neoplásicos
ECSP16072034A (es) Inhibidores de diacilglicerol aciltransferasa 2 para alteraciones metabólicas y desórdenes relacionados
MX377273B (es) Ciclopropilamina como inhibidor de la desmetilasa 1 específica de lisinas (lsd1).
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
CL2015002571A1 (es) Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático.
UY39413A (es) Compuestos inhibidores de metaloenzimas
MX2017009044A (es) Metodo para el tratamiento de malignidades.
MX2019001011A (es) Compuestos farmaceuticos.
CR20160352A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
EA201890815A1 (ru) Аминокислотные композиции с модифицированным высвобождением для перорального введения